Cancer is a complex heterogenic disease with significant therapeutic challenges. The presence of cancer stem cells (CSCs) in cancer tissue orchestrates tumor growth, progression, and metastasis, the tumor heterogeneity, disease relapse, and therapeutic resistance. Hence, it is imperative to explore how progenitor or cancer-initiating cells acquire stemness features and reprogram different biological mechanisms to maintain their sustained oncogenicity. Interestingly, deregulation of F-box proteins (FBPs) is crucial for cancer stemness features, including drug resistance and disease relapse. In this review, we highlight recent updates on the clinical significance of targeting FBPs in cancer therapy, with emphasis on eliminating CSCs and associated therapeutic challenges. Moreover, we also discuss novel strategies for the selective elimination of CSCs by targeting FBPs.

癌症是一种复杂的异源性疾病，具有重大的治疗挑战。癌症组织中癌症干细胞 (CSC) 的存在协调了肿瘤的生长、进展和转移、肿瘤异质性、疾病复发和治疗耐药性。因此，必须探索祖细胞或癌症起始细胞如何获得干细胞特征并重新编程不同的生物学机制以维持其持续的致癌性。有趣的是，F-box 蛋白 (FBP) 的失调对于癌症干性特征至关重要，包括耐药性和疾病复发。在这篇综述中，我们重点介绍了靶向 FBP 在癌症治疗中的临床意义的最新更新，重点是消除 CSC 和相关的治疗挑战。而且，